Pharma Reaserch Prod Co Ltd (214450) — Working Capital to Net Assets Ratio
Pharma Reaserch Prod Co Ltd (214450) has a Working Capital to Net Assets ratio of 89.7% as of December 2025. Working capital of ₩649.07 Billion (current assets of ₩759.54 Billion minus current liabilities of ₩110.47 Billion) is measured against net assets of ₩723.88 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Pharma Reaserch Prod Co Ltd (214450) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Pharma Reaserch Prod Co Ltd Working Capital to Net Assets (2015–2025)
This chart shows how Pharma Reaserch Prod Co Ltd's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2015 to 2025. As of December 2025, the ratio stands at 89.7%, reflecting working capital of ₩649.07 Billion against net assets of ₩723.88 Billion KRW. Check how tangible is Pharma Reaserch Prod Co Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Pharma Reaserch Prod Co Ltd (2015–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Pharma Reaserch Prod Co Ltd from 2015 to 2025, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Pharma Reaserch Prod Co Ltd market capitalisation.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 89.7% | ₩649.07 Billion | ₩723.88 Billion | ₩759.54 Billion | ₩110.47 Billion | ▲ +6.8 pp |
| 2024 | 82.8% | ₩471.72 Billion | ₩569.44 Billion | ₩554.54 Billion | ₩82.82 Billion | ▲ +41.6 pp |
| 2023 | 41.2% | ₩190.57 Billion | ₩462.19 Billion | ₩256.47 Billion | ₩65.90 Billion | ▼ -15.0 pp |
| 2022 | 56.2% | ₩193.09 Billion | ₩343.50 Billion | ₩247.34 Billion | ₩54.25 Billion | ▲ +4.2 pp |
| 2021 | 52.0% | ₩158.79 Billion | ₩305.44 Billion | ₩206.79 Billion | ₩48.01 Billion | ▲ +14.7 pp |
| 2020 | 37.3% | ₩91.55 Billion | ₩245.42 Billion | ₩127.40 Billion | ₩35.85 Billion | ▼ -3.8 pp |
| 2019 | 41.1% | ₩85.88 Billion | ₩209.07 Billion | ₩104.47 Billion | ₩18.59 Billion | ▼ -4.6 pp |
| 2018 | 45.7% | ₩90.29 Billion | ₩197.62 Billion | ₩105.77 Billion | ₩15.48 Billion | ▼ -13.3 pp |
| 2017 | 59.0% | ₩105.47 Billion | ₩178.85 Billion | ₩112.34 Billion | ₩6.86 Billion | ▼ -11.1 pp |
| 2016 | 70.1% | ₩120.26 Billion | ₩171.64 Billion | ₩126.47 Billion | ₩6.21 Billion | ▼ -11.0 pp |
| 2015 | 81.1% | ₩127.06 Billion | ₩156.75 Billion | ₩134.21 Billion | ₩7.16 Billion | — |